Objective:To evaluate the effects of variation Arg16Gly in ADRB2 on clinical response to the salmeterol administered with fluticasone propionate in subjects with asthma. Methods:Sixty-two asthma patients were administered with twice-daily therapy of fluticasone propionate/salmeterol(100 -滋g/50 -滋g) for 12 weeks, followed by a 2-to 4-day run-out period. Using direct DNA sequencing, five SNPs in the promoter and coding block regions of ADRB2 were determined in sixty-two asthma patients, and haplotypes were combined. Results:①There was sustained and significant improvement respectively(P < 0.001) in all measurements of asthma control(PEF, FEV1, albuterol use and asthma symptom score) in subjects receiving salmeterol, compared with baseline, regardless of Arg16Gly genotype. PEF increased with(114.4 ± 21.5)L/min,(100.3 ± 14.7)L/min and(103.3 ± 23.7)L/min in subjects with the Arg/Arg, Gly/Gly and Arg/Gly genotypes respectively, compared with baseline. While, there was no significant difference in the improvement among three genotypes. ②Responses did not be modified by haplotype pairs. ③During the run-out period, all subjects had similar decreases in measurements of asthma control, with no differences among genotypes. Conclusion:Response to salmeterol does not vary with ADRB2 genotypes after chronic dosing with an inhaled corticosteroid. However, larger prospective clinical pharmacogenetic studies to evaluate haplotypes across different ethnic/racial groups, as well as genetic epidemiologic studies, are further needed to help elucidate this field.